This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Brun JL, Feyler A, Chene G et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21–27.
Yancik R . Ovarian cancer: age contrasts in incidence, histology, disease, stage at diagnosis, and mortality. Cancer 1993; 71: 517–523.
Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with haematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302–1308.
Stiff PJ, Bayer R, Kerger C . High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309–1317.
Norton L, Day R . Potential innovations in scheduling of cancer chemotherapy. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds.). Important Advances in Oncology. Lippincott: Philadelphia, PA, 1991; pp 57–72.
Viens P, Maraninchi D, Legros M et al. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinoma: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227–233.
Schilder RJ, Gallo JM, Millenson MM et al. Phase I of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral blood stem cell support as front-line therapy. J Clin Oncol 2001; 19: 1183–1194.
Donato ML, Gershenson DM, Wharton JT et al. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 2001; 82: 420–426.
Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651–659.
Lotz JP, Boulec C, Andre T et al. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and tenoposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 1996; 77: 2550–2559.
Stiff PJ, Veum-Stone J, Lazarus HM et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000; 133: 504–515.
Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345–3352.
Aravantinos G, Bufaloukos D, Fountzillas G et al. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 2003; 14: 1094–1099.
D'Agostino G, Amant F, Berteloot P et al. Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88: 266–269.
Boduka DC, Levenback C, Wolf JK et al. Phase II of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 2: 291–297.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magagnoli, M., Masci, G., Castagna, L. et al. Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer. Bone Marrow Transplant 33, 1261–1262 (2004). https://doi.org/10.1038/sj.bmt.1704527
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704527